Exenatide effects on statin pharmacokinetics and lipid response
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Exenatide is an adjunctive treatment for type 2 diabetes. Many patients with type 2 diabetes have dyslipidemia, which requires treatment with three hydroxy-3-methyl glutaryl coenzyme (HMG-CoA) reductase inhibitors (statins), hence, concurrent use of exenatide and statins is likely. Exenatide slows gastric emptying, which may alter the absorption rate of co-administered oral medications. Thus, the potential interaction between exenatide and statins was evaluated in two study settings. METHODS: In an open-label, fixed-sequence, clinical pharmacology study, the plasma pharmacokinetics of lovastatin (40 mg after breakfast) in the presence and absence of exenatide (10 microg before breakfast and dinner) was evaluated in 21 healthy subjects. In a second clinical setting, changes in lipid profiles and statin dosage over 30 weeks in patients with type 2 diabetes were retrospectively compared (n = 180 exenatide 10 microg twice daily (BID), n = 168 placebo BID) in a combined analysis of three placebo-controlled, randomized exenatide Phase 3 trials. RESULTS: In healthy subjects, exenatide decreased mean lovastatin area under the plasma concentration time curve from zero to infinity (AUC0-infinity) and maximum plasma concentration (Cmax) by 40 and 28%, respectively, and increased median time to maximum plasma concentration (tmax) by 4 hours. In the exenatide Phase 3 trials, 30-week changes from baseline for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol, triglycerides and statin dosage were not significantly different between the exenatide and placebo groups treated with statins. CONCLUSIONS: Despite observed changes in lovastatin bioavailability in the pharmacokinetic drug interaction study, exenatide did not negatively affect long-term lipid profiles or statin dosage in patients with concurrent statin therapy. Thus, co-administration of exenatide does not require adjustment in statin dosage.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Likewise, exenatide resulted in reduced Cmax, delayed tmax and reduced AUC of lovastatin [20].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [20]
In the citing paper
“However, an analysis of 966 subjects who received statins in Phase 3 trials of exenatide (51% atorvastatin, 31% simvastatin, 11% pravastatin, 5% lovastatin, 3% fluvastatin) showed comparable lipid-lowering statin effects compared to placebo [20].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [20]
Citations
Cites
Still being checked.
Cited by
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Wetmore, B. A., Wambaugh, J. F., Allen, B., Ferguson, S. S., Sochaski, M. A., Setzer, R. W., Houck, K. A., Strope, C. L., Cantwell, K., Judson, R. S., et al. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv171 · Cited by 234
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
Advances in the Treatment of Type 2 Diabetes Mellitus
Israili, Z. H. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181afbf51 · Cited by 165
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D. (2024) · Drug Safety · doi:10.1007/s40264-023-01392-3 · Cited by 97
Wetmore, B. A., Allen, B., M.A., H. J. C. I., Parker, T. A., Wambaugh, J. F., Almond, L. M., Sochaski, M. A., & Thomas, R. S. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu169 · Cited by 106
Yap, M. K. K., & Misuan, N. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13169 · Cited by 92
Lennernäs, H. (2009) · Molecular Pharmaceutics · doi:10.1021/mp9000876 · Cited by 82
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
Jespersen, M. J., Knop, F. K., & Christensen, M. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.731394 · Cited by 60
Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects
Drab, S. R. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.609 · Cited by 58
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, J. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.024 · Cited by 47
Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist
Young, M. A., Wald, J. A., Matthews, J. E., Scott, R., Hodge, R. J., Zhi, H., & Reinhardt, R. R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2836 · Cited by 41
The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes
Russell-Jones, D. L. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02465.x · Cited by 42
Malm-Erjefält, M., Ekblom, M., Vouis, J., Zdravkovic, M., & Lennernäs, H. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00278 · Cited by 36
Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Charbonnel, B. H., & Cariou, B. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01317.x · Cited by 42
Kothare, P. A., Seger, M. E., Northrup, J., Mace, K., Mitchell, M. I., & Linnebjerg, H. (2012) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-12-8 · Cited by 35
“Drug-drug interaction studies with digoxin [8], warfarin [9], lovastatin [10], and lisinopril [11] have demonstrated that concomitant exenatide treatment reduced the maximum plasma concentrations (Cmax) and delayed the Tmax for these drugs, both of which are consistent with slowing of gastric emptying.”
BackgroundResultSelf-citationDrug-Drug Interactions with Glucagon-Like Peptide-1 Receptor Agonists
Hurren, K. M., & Pinelli, N. R. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q583 · Cited by 34
Li, J., Wang, L., Li, Z., & Pan, W. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.05119.x · Cited by 32
Pharmacotherapy of Type 2 Diabetes Mellitus: An Update on Drug–Drug Interactions
Amin, M., & Suksomboon, N. (2014) · Drug Safety · doi:10.1007/s40264-014-0223-2 · Cited by 35
Non-insulin anti-diabetic drugs: An update on pharmacological interactions
Ruscica, M., Baldessin, L., Boccia, D., Racagni, G., & Mitro, N. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.005 · Cited by 32
Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes
Molina‐Vega, M., Muñoz‐Garach, A., & Tinahones, F. J. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1420160 · Cited by 16
Pharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists
Maideen, N. M. P. (2019) · Journal of Analytical & Pharmaceutical Research · doi:10.15406/japlr.2019.08.00311 · Cited by 14
Nusca, A., Piccirillo, F., Bernardini, F., Filippis, A. D., Coletti, F., Mangiacapra, F., Ricottini, E., Melfi, R., Gallo, P., Cammalleri, V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137261 · Cited by 14
Can Therapies That Target the Incretin System Improve Our Ability to Treat Type 2 Diabetes?
Bell, T. J., & Wright, E. E. (2010) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)30560-5 · Cited by 6
Nagai, Y., Mukai, K., Otsuki, M., Kimura, T., Kozawa, J., Nishizawa, H., Maeda, N., Matsuoka, T., Iwahashi, H., Imagawa, A., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1585-18 · Cited by 7
Bogman, K., Brumm, J., Hofmann, C., Giraudon, M., Niggli, M., Sturm, C., Sauter, A., Sturm, S., Mangold, B., & Schmitt, C. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00757-1 · Cited by 5
Glucagon-like peptide and its receptor agonists for the treatment of rheumatic diseases
Chamchoum, E., Katrib, N., Nassif, N., Ratel, Y., & Rida, M. A. (2025) · World Journal of Experimental Medicine · doi:10.5493/wjem.v15.i3.107020 · Cited by 7
Exenatide: incretin therapy for patients with Type 2 diabetes mellitus
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.6.671 · Cited by 5
Bode, B. W., & Amin, A. (2009) · Hospital Practice · doi:10.3810/hp.2009.12.249 · Cited by 2
Pharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists
Maideen, N. M. P. (2019) · Journal of Analytical & Pharmaceutical Research · doi:10.15406/japlr.2019.08.00310 · Cited by 7
Zbârcea, C. E., Marineci, C., Valeanu, A., Chiriţă, C., & Șeremet, O. C. (2026) · Diabetology · doi:10.3390/diabetology7060108 · Cited by 3
How incretin-based therapies address the spectrum of physiologic disturbance in type 2 diabetes
(2010) · The Internet Journal of Academic Physician Assistants · doi:10.5580/172c · Cited by 1
[Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
Reboldi, G. (2009) · PubMed
Exenatide — A Novel Treatment to Manage Type 2 Diabetes Mellitus
Puig‐Domingo, M., & Ríos, A. G. (2007) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2007.00.01.23 · Cited by 1
(2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282fba8b4
Metadata
- Authors
- Kothare, P. A., Linnebjerg, H., Skrivanek, Z., Reddy, S., Mace, K., Pena, A., Han, J., Fineman, M., & Mitchell, M.
- Affiliations
- Eli Lilly (United States) (US)
- Venue
- Int. Journal of Clinical Pharmacology and Therapeutics
- Publisher
- Dustri-Verlgag Dr. Karl Feistle
- Published
- 2007-02-01
- Volume
- 45
- Issue
- 02
- Pages
- 114-120
- ISSN
- 0946-1965 (ISSN-L)
- OpenAlex
- W2020787870
- Cited by
- 36
- References
- 0
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2022: 1 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 3 · 2012: 3
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Clinical Pharmacology and Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- exenatide, statins, lovastatin, drug-drug interactions, pharmacokinetics, bioavailability, type 2 diabetes, dyslipidemia, lipid profile, statin dose adjustment, gastric emptying
- MeSH terms
- Exenatide, Adolescent, Adult, Aged, Diabetes Mellitus, Type 2, Drug Interactions, Female, Humans, Hypoglycemic Agents, Lipids, Lovastatin, Male, Middle Aged, Peptides, Venoms, Cross-Over Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.